Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Bristol-Myers Squibb
BicycleTx Limited
Nanobiotix
Memgen, Inc.
Incyte Corporation
Bristol-Myers Squibb
Exelixis
Compugen Ltd
Tempest Therapeutics
Nektar Therapeutics
Calithera Biosciences, Inc
Incyte Corporation
Duke University
Infinity Pharmaceuticals, Inc.
Bristol-Myers Squibb
Sheba Medical Center
MultiVir, Inc.
Celgene